eazySNP System
Avoid ineffective treatment and infection control management!
Definitive resistance determination in just 45 minutes!
Background: Echinocandin resistance in
Candidozyma auris
C. auris is a global, healthcare-associated pathogen with high azole resistance. Echinocandins therefore remain the first-line treatment of choice; however, cases of treatment-induced echinocandin resistance have increased significantly in recent years. Genome analyses show that this resistance is very often associated with mutations in hotspot regions of the FKS1 gene (which encodes β-glucan synthase). The most common point mutations responsible are S639F, S639Y, and S639P, which this test detects with high specificity.
eazySNP C. auris FKS1 S639: A rapid, targeted molecular test for early detection of resistant C. auris strains, with no sequencing required!
The diagnostic benefit is further enhanced when used in combination with the eazyplex® Candida auris Kit.
Clinical and diagnostic benefits:
- Real-time treatment guidance: Detection of specific FKS1 mutations supports early adjustment of antifungal therapy.
- Surveillance and infection control: Fast, specific diagnostics support outbreak and cluster management and strengthen antibiotic stewardship programs.
- Focus on high-risk scenarios: Particularly relevant for urinary tract and colonization isolates, where low drug exposure is often linked to the development of resistance.
By specifically detecting resistance-associated SNP variants, eazySNP provides actionable information with immediate value for clinics and laboratories.
The kit combines LAMP technology with CRISPR-Cas-based detection and provides information on echinocandin resistance in C. auris directly from a single colony in less than 1 hour. No complex, time-consuming, and costly DNA extraction is required. Integrated quality control mechanisms ensure valid result reporting.
